Grifols, a global producer of plasma-derived medicines and developer of diagnostic solutions, has entered into a transaction to acquire the remaining equity of Alkahest, Inc. for $146 million. The transaction, subject to customary approvals, is expected to close in early 2021. Alkahest, a Silicon Valley-based biotechnology company was founded on research into the therapeutic use of plasma proteins in combating diseases associated with aging as identified in the Stanford University lab of Ton...